CX4 series is a contrast agent that can be utilized during MRI; it is a nanozyme, utilizing CX synthetic platform technology, that solves contrast toxicity currently plaguing existing technologies. It is an innovative material, based on novel nanocatalytic technology, with excellent contrast effects and biostability.
The CX4 series exhibits optimal contrast effects: inorganic elements show optimal contrast in the MRI, comparable to conventional contrast agent.
Based on nanocatalytic technology, the CX4 series is non-toxic, has high biostability, and does not suffer from ion elimination, a problem with conventional contrast agent. Moreover, biocompatibility is secured by treatment with a special polymer.
Advancing beyond the limitations of previous studies, the structural stability of nanocatalysts ensures that the CX4 series is adaptable for use in patients with underlying diseases that have been recalcitrant to imaging with conventional contrast agent.
Characteristic of nanocatalytic technology, the physical aspects of the nanozymes are extremely customizable. Therefore, the CX4 series can be applied as a contrast agent for the imaging of various nonspecific lesions and organs in the body.